Cayman
Showing 19951–20100 of 45550 results
-
Immunogen: Peptide corresponding to amino acid residues from the C-terminus of rat ERK/MAPK • Host: Rabbit • Species Reactivity: (+) Human, Mouse, Rat • Applications: ICC and WB • MW = ~44 and 42 kDa for ERK1/MAPK3 and ERK2/MAPK1, respectively
Brand:CaymanSKU:29263- 100 µl Extracellular-signal-regulated kinase/mitogen-activated protein kinases (ERK/MAPKs) are a widely conserved family of serine/threonine protein kinases and essential components of the MAP kinase signaling cascade.{53684,53685} Upon extracellular stimulation with mitogens, growth factors, or cytokines, a sequential three-part signaling cascade is initiated that terminates with phosphorylation of ERK/MAPK by MEK1 or MEK2. Activated ERK/MAPK is translocated to the nucleus where it regulates transcription factor activity and gene transcription for a variety of cellular processes including cell proliferation, differentiation, and stress response. Misregulation of the MAP kinase cascade drives development of various cancers. ERK1/MAPK3 and ERK2/MAPK1 are two key members of the ERK/MAPK family encoded by MAPK3 and MAPK1, respectively, in humans and are expressed in all tissues. Cayman’s ERK/MAPK Polyclonal Antibody can be used for immunocytochemistry (ICC) and Western blot (WB) applications. The antibody recognizes ERK1/MAPK3 and ERK2/MAPK1 at approximately 44 and 42 kDa, respectively from human, mouse, and rat samples.
Brand:CaymanSKU:29263 - 100 µlAvailable on backorder
Immunogen: Peptide corresponding to amino acid residues from the C-terminus of rat ERK/MAPK • Host: Rabbit • Species Reactivity: (+) Human, Mouse, Rat • Applications: ICC and WB • MW = ~44 and 42 kDa for ERK1/MAPK3 and ERK2/MAPK1, respectively
Brand:CaymanSKU:29263- 100 µlAvailable on backorder
Erlotinib is a tyrosine kinase inhibitor which acts on the epidermal growth factor receptor (EGFR), inhibiting EGFR-associated kinase activity (IC50 = 2.5 µM).{18354,18362} This inhibits tumor growth in human head and neck carcinoma HN5 tumor xenografts in mice with an ED50 value of 9 mg/kg.{18354} Erlotinib also suppresses cyclin-dependent kinase 2 (Cdk2) activity in breast cancer cells (IC50 = 4.6 µM) and JAK2 mutant JAK2V617F positive hematopoietic progenitor cells (IC50 = 5 µM), which is associated with polycythemia vera, idiopathic myelofibrosis, and essential thrombocythemia.{16061,18355} Formulations containing erlotinib have been used to treat certain forms of cancer, including non-small cell lung cancer.{18351,17857}
Brand:CaymanSKU:10483 - 1 gAvailable on backorder
Erlotinib is a tyrosine kinase inhibitor which acts on the epidermal growth factor receptor (EGFR), inhibiting EGFR-associated kinase activity (IC50 = 2.5 µM).{18354,18362} This inhibits tumor growth in human head and neck carcinoma HN5 tumor xenografts in mice with an ED50 value of 9 mg/kg.{18354} Erlotinib also suppresses cyclin-dependent kinase 2 (Cdk2) activity in breast cancer cells (IC50 = 4.6 µM) and JAK2 mutant JAK2V617F positive hematopoietic progenitor cells (IC50 = 5 µM), which is associated with polycythemia vera, idiopathic myelofibrosis, and essential thrombocythemia.{16061,18355} Formulations containing erlotinib have been used to treat certain forms of cancer, including non-small cell lung cancer.{18351,17857}
Brand:CaymanSKU:10483 - 250 mgAvailable on backorder
Erlotinib is a tyrosine kinase inhibitor which acts on the epidermal growth factor receptor (EGFR), inhibiting EGFR-associated kinase activity (IC50 = 2.5 µM).{18354,18362} This inhibits tumor growth in human head and neck carcinoma HN5 tumor xenografts in mice with an ED50 value of 9 mg/kg.{18354} Erlotinib also suppresses cyclin-dependent kinase 2 (Cdk2) activity in breast cancer cells (IC50 = 4.6 µM) and JAK2 mutant JAK2V617F positive hematopoietic progenitor cells (IC50 = 5 µM), which is associated with polycythemia vera, idiopathic myelofibrosis, and essential thrombocythemia.{16061,18355} Formulations containing erlotinib have been used to treat certain forms of cancer, including non-small cell lung cancer.{18351,17857}
Brand:CaymanSKU:10483 - 5 gAvailable on backorder
Erlotinib is a tyrosine kinase inhibitor which acts on the epidermal growth factor receptor (EGFR), inhibiting EGFR-associated kinase activity (IC50 = 2.5 µM).{18354,18362} This inhibits tumor growth in human head and neck carcinoma HN5 tumor xenografts in mice with an ED50 value of 9 mg/kg.{18354} Erlotinib also suppresses cyclin-dependent kinase 2 (Cdk2) activity in breast cancer cells (IC50 = 4.6 µM) and JAK2 mutant JAK2V617F positive hematopoietic progenitor cells (IC50 = 5 µM), which is associated with polycythemia vera, idiopathic myelofibrosis, and essential thrombocythemia.{16061,18355} Formulations containing erlotinib have been used to treat certain forms of cancer, including non-small cell lung cancer.{18351,17857}
Brand:CaymanSKU:10483 - 500 mgAvailable on backorder
Erlotinib-d6 (hydrochloride) contains six deuterium atoms located on the methoxy group. It is intended for use as an internal standard for the quantification of erlotinib (Item No. 10483) by GC- or LC-MS. Erlotinib is a tyrosine kinase inhibitor that acts on the epidermal growth factor receptor (EGFR), inhibiting EGFR-associated kinase activity (IC50 = 2.5 µM).{18353,18362} This inhibits tumor growth in human head and neck carcinoma (HN5) tumor xenografts in mice with an ED50 value of 9 mg/kg.{18353} Erlotinib also suppresses cyclin-dependent kinase 2 (Cdk2) activity in breast cancer cells (IC50 = 4.6 µM) and JAK2 mutant JAK2V617F (IC50 = 5 µM), which is associated with polycythemia vera, idiopathic myelofibrosis, and essential thrombocythemia.{16061,18355} Formulations containing erlotinib are used to treat certain forms of cancer, including non-small cell lung cancer.{18351,17857}
Brand:CaymanSKU:22101 -Out of stock
Ertapenem is a long-acting, broad-spectrum antibiotic that is in the β-lactam subclass known as carbapenems.{27718,27720,27719} It inhibits the synthesis of bacterial cell walls by attaching to penicillin-binding proteins. Ertapenem is effective against Gram-positive and Gram-negative bacteria.{32520,32521} Resistance to ertapenem results from the expression of certain β-lactamases and carbapenemases.{32519}
Brand:CaymanSKU:20523 -Available on backorder
Ertapenem is a long-acting, broad-spectrum antibiotic that is in the β-lactam subclass known as carbapenems.{27718,27720,27719} It inhibits the synthesis of bacterial cell walls by attaching to penicillin-binding proteins. Ertapenem is effective against Gram-positive and Gram-negative bacteria.{32520,32521} Resistance to ertapenem results from the expression of certain β-lactamases and carbapenemases.{32519}
Brand:CaymanSKU:20523 -Available on backorder
Ertapenem is a long-acting, broad-spectrum antibiotic that is in the β-lactam subclass known as carbapenems.{27718,27720,27719} It inhibits the synthesis of bacterial cell walls by attaching to penicillin-binding proteins. Ertapenem is effective against Gram-positive and Gram-negative bacteria.{32520,32521} Resistance to ertapenem results from the expression of certain β-lactamases and carbapenemases.{32519}
Brand:CaymanSKU:20523 -Available on backorder
Ertapenem is a long-acting, broad-spectrum antibiotic that is in the β-lactam subclass known as carbapenems.{27718,27720,27719} It inhibits the synthesis of bacterial cell walls by attaching to penicillin-binding proteins. Ertapenem is effective against Gram-positive and Gram-negative bacteria.{32520,32521} Resistance to ertapenem results from the expression of certain β-lactamases and carbapenemases.{32519}
Brand:CaymanSKU:20523 -Available on backorder
Erteberel is a potent and selective agonist of estrogen receptor β (ERβ; Ki = 1.54 nM; EC50 = 3.61 nM).{34786} Erteberel reduces the viability of patient-derived, ERβ+ primary glioblastoma (GBM) cells, significantly reducing in vitro colony formation and inducing apoptosis.{34787} It induces G2/M arrest and sensitizes GBM cells to the chemotherapeutic agents cisplatin (Item No. 13119), lomustine, and temozolomide (Item No. 14163) in vitro. Treatment with erteberel reduces GBM progression in and increases survival of orthotopic and syngeneic GBM mouse models. Erteberel also induces dose-dependent reduction in prostate weight with no effect on levels of circulating testosterone (Item Nos. 15645 | ISO60154) or dihydrotestosterone (Item No. 15874) in a rat model of benign prostatic hyperplasia (BPH).{34786} Formulations containing erteberel have been tested in phase II clinical trials for treatment of BPH in healthy men.{34785}
Brand:CaymanSKU:22130 -Out of stock
Erteberel is a potent and selective agonist of estrogen receptor β (ERβ; Ki = 1.54 nM; EC50 = 3.61 nM).{34786} Erteberel reduces the viability of patient-derived, ERβ+ primary glioblastoma (GBM) cells, significantly reducing in vitro colony formation and inducing apoptosis.{34787} It induces G2/M arrest and sensitizes GBM cells to the chemotherapeutic agents cisplatin (Item No. 13119), lomustine, and temozolomide (Item No. 14163) in vitro. Treatment with erteberel reduces GBM progression in and increases survival of orthotopic and syngeneic GBM mouse models. Erteberel also induces dose-dependent reduction in prostate weight with no effect on levels of circulating testosterone (Item Nos. 15645 | ISO60154) or dihydrotestosterone (Item No. 15874) in a rat model of benign prostatic hyperplasia (BPH).{34786} Formulations containing erteberel have been tested in phase II clinical trials for treatment of BPH in healthy men.{34785}
Brand:CaymanSKU:22130 -Out of stock
Erteberel is a potent and selective agonist of estrogen receptor β (ERβ; Ki = 1.54 nM; EC50 = 3.61 nM).{34786} Erteberel reduces the viability of patient-derived, ERβ+ primary glioblastoma (GBM) cells, significantly reducing in vitro colony formation and inducing apoptosis.{34787} It induces G2/M arrest and sensitizes GBM cells to the chemotherapeutic agents cisplatin (Item No. 13119), lomustine, and temozolomide (Item No. 14163) in vitro. Treatment with erteberel reduces GBM progression in and increases survival of orthotopic and syngeneic GBM mouse models. Erteberel also induces dose-dependent reduction in prostate weight with no effect on levels of circulating testosterone (Item Nos. 15645 | ISO60154) or dihydrotestosterone (Item No. 15874) in a rat model of benign prostatic hyperplasia (BPH).{34786} Formulations containing erteberel have been tested in phase II clinical trials for treatment of BPH in healthy men.{34785}
Brand:CaymanSKU:22130 -Out of stock
Ertugliflozin potently inhibits the sodium-glucose cotransporter 2 (SGLT2), increasing the excretion of glucose with a 2,000-fold selectivity over SGLT1 (IC50 = 0.877 and 1,960 nM, respectively, for human isoforms in vitro).{33645} Inhibiting renal glucose reabsorption in this way offers an insulin-independent alternative to controlling blood glucose concentrations in patients with type 2 diabetes mellitus.{19849,33644} In Phase III clinical trials at doses of 5 and 15 mg, ertugliflozin reduced plasma glucose and HbA1c levels as well as decreased body weight.{33646,33643}
Brand:CaymanSKU:21507 -Out of stock
Ertugliflozin potently inhibits the sodium-glucose cotransporter 2 (SGLT2), increasing the excretion of glucose with a 2,000-fold selectivity over SGLT1 (IC50 = 0.877 and 1,960 nM, respectively, for human isoforms in vitro).{33645} Inhibiting renal glucose reabsorption in this way offers an insulin-independent alternative to controlling blood glucose concentrations in patients with type 2 diabetes mellitus.{19849,33644} In Phase III clinical trials at doses of 5 and 15 mg, ertugliflozin reduced plasma glucose and HbA1c levels as well as decreased body weight.{33646,33643}
Brand:CaymanSKU:21507 -Out of stock
Ertugliflozin potently inhibits the sodium-glucose cotransporter 2 (SGLT2), increasing the excretion of glucose with a 2,000-fold selectivity over SGLT1 (IC50 = 0.877 and 1,960 nM, respectively, for human isoforms in vitro).{33645} Inhibiting renal glucose reabsorption in this way offers an insulin-independent alternative to controlling blood glucose concentrations in patients with type 2 diabetes mellitus.{19849,33644} In Phase III clinical trials at doses of 5 and 15 mg, ertugliflozin reduced plasma glucose and HbA1c levels as well as decreased body weight.{33646,33643}
Brand:CaymanSKU:21507 -Out of stock
Ertugliflozin potently inhibits the sodium-glucose cotransporter 2 (SGLT2), increasing the excretion of glucose with a 2,000-fold selectivity over SGLT1 (IC50 = 0.877 and 1,960 nM, respectively, for human isoforms in vitro).{33645} Inhibiting renal glucose reabsorption in this way offers an insulin-independent alternative to controlling blood glucose concentrations in patients with type 2 diabetes mellitus.{19849,33644} In Phase III clinical trials at doses of 5 and 15 mg, ertugliflozin reduced plasma glucose and HbA1c levels as well as decreased body weight.{33646,33643}
Brand:CaymanSKU:21507 -Out of stock
Erucin is an isothiocyanate derived from glucoerucin, a glucosinolate predominant in arugula (Eruca sativa Mill.) and other cruciferous vegetables. At 2.5-5 μM erucin can induce significant neuroprotective and antioxidant effects, increasing both total glutathione levels and total antioxidant capacity at the cytosolic level in dopaminergic-like neuroblastoma SH-SY5Y cells.{21910} Growth inhibition, cell cycle regulation, apoptosis, and induction of detoxification enzymes have all been reported from use of erucin in prostate, lung, liver, and colon cancer cells.{21909,21908}
Brand:CaymanSKU:- Erucin is an isothiocyanate derived from glucoerucin, a glucosinolate predominant in arugula (Eruca sativa Mill.) and other cruciferous vegetables. At 2.5-5 μM erucin can induce significant neuroprotective and antioxidant effects, increasing both total glutathione levels and total antioxidant capacity at the cytosolic level in dopaminergic-like neuroblastoma SH-SY5Y cells.{21910} Growth inhibition, cell cycle regulation, apoptosis, and induction of detoxification enzymes have all been reported from use of erucin in prostate, lung, liver, and colon cancer cells.{21909,21908}
Brand:CaymanSKU:- Erucin is an isothiocyanate derived from glucoerucin, a glucosinolate predominant in arugula (Eruca sativa Mill.) and other cruciferous vegetables. At 2.5-5 μM erucin can induce significant neuroprotective and antioxidant effects, increasing both total glutathione levels and total antioxidant capacity at the cytosolic level in dopaminergic-like neuroblastoma SH-SY5Y cells.{21910} Growth inhibition, cell cycle regulation, apoptosis, and induction of detoxification enzymes have all been reported from use of erucin in prostate, lung, liver, and colon cancer cells.{21909,21908}
Brand:CaymanSKU:-
Erythrodiol is a triterpene that has been found in olive oil and has diverse biological activities.{46856,46857,46858,46859} It induces relaxation of isolated rat aortic rings precontracted with phenylephrine (EC50 = 3.38 µM).{46856} Erythrodiol inhibits the growth of HT-29 adenocarcinoma cells (EC50 = 48.8 µM).{46857} It induces production of reactive oxygen species (ROS) and apoptosis in MCF-7 cells when used at a concentration of 100 µM.{46858} Topical administration of erythrodiol (0.5 mg/ear) reduces ear edema and myeloperoxidase (MPO) activity induced by phorbol 12-myristate 13-acetate (TPA; Item No. 10008014) in mice.{46859}
Brand:CaymanSKU:30135 - 10 mgAvailable on backorder
Erythrodiol is a triterpene that has been found in olive oil and has diverse biological activities.{46856,46857,46858,46859} It induces relaxation of isolated rat aortic rings precontracted with phenylephrine (EC50 = 3.38 µM).{46856} Erythrodiol inhibits the growth of HT-29 adenocarcinoma cells (EC50 = 48.8 µM).{46857} It induces production of reactive oxygen species (ROS) and apoptosis in MCF-7 cells when used at a concentration of 100 µM.{46858} Topical administration of erythrodiol (0.5 mg/ear) reduces ear edema and myeloperoxidase (MPO) activity induced by phorbol 12-myristate 13-acetate (TPA; Item No. 10008014) in mice.{46859}
Brand:CaymanSKU:30135 - 25 mgAvailable on backorder
Erythrodiol is a triterpene that has been found in olive oil and has diverse biological activities.{46856,46857,46858,46859} It induces relaxation of isolated rat aortic rings precontracted with phenylephrine (EC50 = 3.38 µM).{46856} Erythrodiol inhibits the growth of HT-29 adenocarcinoma cells (EC50 = 48.8 µM).{46857} It induces production of reactive oxygen species (ROS) and apoptosis in MCF-7 cells when used at a concentration of 100 µM.{46858} Topical administration of erythrodiol (0.5 mg/ear) reduces ear edema and myeloperoxidase (MPO) activity induced by phorbol 12-myristate 13-acetate (TPA; Item No. 10008014) in mice.{46859}
Brand:CaymanSKU:30135 - 5 mgAvailable on backorder
Erythrodiol is a triterpene that has been found in olive oil and has diverse biological activities.{46856,46857,46858,46859} It induces relaxation of isolated rat aortic rings precontracted with phenylephrine (EC50 = 3.38 µM).{46856} Erythrodiol inhibits the growth of HT-29 adenocarcinoma cells (EC50 = 48.8 µM).{46857} It induces production of reactive oxygen species (ROS) and apoptosis in MCF-7 cells when used at a concentration of 100 µM.{46858} Topical administration of erythrodiol (0.5 mg/ear) reduces ear edema and myeloperoxidase (MPO) activity induced by phorbol 12-myristate 13-acetate (TPA; Item No. 10008014) in mice.{46859}
Brand:CaymanSKU:30135 - 50 mgAvailable on backorder
Erythromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by targeting the 50S ribosomal subunit, blocking the progression of nascent polypeptide chains.{22680} It is active against a host of bacterial genera, including Streptococcus, Staphylococcus, and Haemophilus (MIC90s = 0.015-2.0 mg/l).{22758} Erythromycin (10-40 mg/kg) dose-dependently inhibits the growth of S. aureus in a mouse model of thigh infection.{42209} It also inhibits the cytochrome P450 (CYP450) isoform CYP3A4 in vitro with IC50 values of 33 and 27.3 µM for α-hydroxytriazolam and 4-hydroxytriazolam formation, respectively, following administration of triazolam, which is known to be metabolized primarily by CYP3A4.{22760,42210} Formulations containing erythromycin have been used in the treatment of bacterial respiratory and skin infections, pertussis, and a variety of other bacterial infections.
Brand:CaymanSKU:-Out of stock
Erythromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by targeting the 50S ribosomal subunit, blocking the progression of nascent polypeptide chains.{22680} It is active against a host of bacterial genera, including Streptococcus, Staphylococcus, and Haemophilus (MIC90s = 0.015-2.0 mg/l).{22758} Erythromycin (10-40 mg/kg) dose-dependently inhibits the growth of S. aureus in a mouse model of thigh infection.{42209} It also inhibits the cytochrome P450 (CYP450) isoform CYP3A4 in vitro with IC50 values of 33 and 27.3 µM for α-hydroxytriazolam and 4-hydroxytriazolam formation, respectively, following administration of triazolam, which is known to be metabolized primarily by CYP3A4.{22760,42210} Formulations containing erythromycin have been used in the treatment of bacterial respiratory and skin infections, pertussis, and a variety of other bacterial infections.
Brand:CaymanSKU:-Out of stock
Erythromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by targeting the 50S ribosomal subunit, blocking the progression of nascent polypeptide chains.{22680} It is active against a host of bacterial genera, including Streptococcus, Staphylococcus, and Haemophilus (MIC90s = 0.015-2.0 mg/l).{22758} Erythromycin (10-40 mg/kg) dose-dependently inhibits the growth of S. aureus in a mouse model of thigh infection.{42209} It also inhibits the cytochrome P450 (CYP450) isoform CYP3A4 in vitro with IC50 values of 33 and 27.3 µM for α-hydroxytriazolam and 4-hydroxytriazolam formation, respectively, following administration of triazolam, which is known to be metabolized primarily by CYP3A4.{22760,42210} Formulations containing erythromycin have been used in the treatment of bacterial respiratory and skin infections, pertussis, and a variety of other bacterial infections.
Brand:CaymanSKU:-Out of stock
Erythromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by targeting the 50S ribosomal subunit, blocking the progression of nascent polypeptide chains.{22680} It is active against a host of bacterial genera, including Streptococcus, Staphylococcus, and Haemophilus (MIC90s = 0.015-2.0 mg/l).{22758} Erythromycin (10-40 mg/kg) dose-dependently inhibits the growth of S. aureus in a mouse model of thigh infection.{42209} It also inhibits the cytochrome P450 (CYP450) isoform CYP3A4 in vitro with IC50 values of 33 and 27.3 µM for α-hydroxytriazolam and 4-hydroxytriazolam formation, respectively, following administration of triazolam, which is known to be metabolized primarily by CYP3A4.{22760,42210} Formulations containing erythromycin have been used in the treatment of bacterial respiratory and skin infections, pertussis, and a variety of other bacterial infections.
Brand:CaymanSKU:-Out of stock
Erythromycin A enol ether is a decomposition product of the macrolide antibiotic, erythromycin A (Item No. 16486).{25101} Erythromycin A enol ether does not retain the antibiotic properties of erythromycin A and has been identified as a β-turn mimic of the peptide hormone motilin, causing duodenal contractions and gastrointestinal distress.{28114} This compound has been used to determine the binding characteristics of ligands of the motilin receptor.{28114}
Brand:CaymanSKU:-Out of stock
Erythromycin A enol ether is a decomposition product of the macrolide antibiotic, erythromycin A (Item No. 16486).{25101} Erythromycin A enol ether does not retain the antibiotic properties of erythromycin A and has been identified as a β-turn mimic of the peptide hormone motilin, causing duodenal contractions and gastrointestinal distress.{28114} This compound has been used to determine the binding characteristics of ligands of the motilin receptor.{28114}
Brand:CaymanSKU:-Out of stock
Erythromycin A enol ether is a decomposition product of the macrolide antibiotic, erythromycin A (Item No. 16486).{25101} Erythromycin A enol ether does not retain the antibiotic properties of erythromycin A and has been identified as a β-turn mimic of the peptide hormone motilin, causing duodenal contractions and gastrointestinal distress.{28114} This compound has been used to determine the binding characteristics of ligands of the motilin receptor.{28114}
Brand:CaymanSKU:-Out of stock
Erythromycin A N-oxide is a potential impurity found in commercial preparations of erythromycin.{35178} Erythromycin (Item No. 16486) is a macrolide antibiotic that inhibits bacterial protein synthesis by targeting the 50S ribosomal subunit, blocking the progression of nascent polypeptide chains.{22680} It is effective against a host of bacterial genera, including Streptococcus, Staphylococcus, and Haemophilus (MIC90s = 0.015-2.0 mg/l).{22758} Erythromycin is known to potently inhibit the cytochrome P450 isoform CYP3A4, which can affect the metabolism of numerous clinically relevant medications.{22760,17924} Erythromycin A N-oxide is also a precursor in the synthesis of clarithromycin (Item No. 19455).{35220}
Brand:CaymanSKU:23642 - 25 mgAvailable on backorder
Erythromycin A N-oxide is a potential impurity found in commercial preparations of erythromycin.{35178} Erythromycin (Item No. 16486) is a macrolide antibiotic that inhibits bacterial protein synthesis by targeting the 50S ribosomal subunit, blocking the progression of nascent polypeptide chains.{22680} It is effective against a host of bacterial genera, including Streptococcus, Staphylococcus, and Haemophilus (MIC90s = 0.015-2.0 mg/l).{22758} Erythromycin is known to potently inhibit the cytochrome P450 isoform CYP3A4, which can affect the metabolism of numerous clinically relevant medications.{22760,17924} Erythromycin A N-oxide is also a precursor in the synthesis of clarithromycin (Item No. 19455).{35220}
Brand:CaymanSKU:23642 - 5 mgAvailable on backorder
Erythromycin C is an intermediate in the biosynthesis of erythromycin (Item No. 16486).{41258} It is also a potential impurity found in commercial preparations of erythromycin. Erythromycin C is half as active or less than erythromycin A or B against most Gram-positive and Gram-negative bacteria tested.{41259}
Brand:CaymanSKU:23478 - 1 mgAvailable on backorder
Erythromycin C is an intermediate in the biosynthesis of erythromycin (Item No. 16486).{41258} It is also a potential impurity found in commercial preparations of erythromycin. Erythromycin C is half as active or less than erythromycin A or B against most Gram-positive and Gram-negative bacteria tested.{41259}
Brand:CaymanSKU:23478 - 5 mgAvailable on backorder
Erythromycin C is an intermediate in the biosynthesis of erythromycin (Item No. 16486).{41258} It is also a potential impurity found in commercial preparations of erythromycin. Erythromycin C is half as active or less than erythromycin A or B against most Gram-positive and Gram-negative bacteria tested.{41259}
Brand:CaymanSKU:23478 - 500 µgAvailable on backorder
Erythromycin (Item No. 16486) is a macrolide antibiotic that inhibits bacterial protein synthesis by targeting the 50S ribosomal subunit, blocking the progression of nascent polypeptide chains.{22680} It is effective against a host of bacterial genera, including Streptococcus, Staphylococcus, and Haemophilus (MIC90s range from 0.015-2.0 mg/l).{22758} Erythromycin is known to potently inhibit the cytochrome P450 isoform CYP3A4, which can affect the metabolism of numerous clinically relevant medications.{22760,20981} Erythromycin lactobionate is a soluble salt of erythromycin that is typically used for intraperitoneal or intravenous injections.{28247,28248}
Brand:CaymanSKU:-Out of stock
Erythromycin (Item No. 16486) is a macrolide antibiotic that inhibits bacterial protein synthesis by targeting the 50S ribosomal subunit, blocking the progression of nascent polypeptide chains.{22680} It is effective against a host of bacterial genera, including Streptococcus, Staphylococcus, and Haemophilus (MIC90s range from 0.015-2.0 mg/l).{22758} Erythromycin is known to potently inhibit the cytochrome P450 isoform CYP3A4, which can affect the metabolism of numerous clinically relevant medications.{22760,20981} Erythromycin lactobionate is a soluble salt of erythromycin that is typically used for intraperitoneal or intravenous injections.{28247,28248}
Brand:CaymanSKU:-Out of stock
Erythromycin (Item No. 16486) is a macrolide antibiotic that inhibits bacterial protein synthesis by targeting the 50S ribosomal subunit, blocking the progression of nascent polypeptide chains.{22680} It is effective against a host of bacterial genera, including Streptococcus, Staphylococcus, and Haemophilus (MIC90s range from 0.015-2.0 mg/l).{22758} Erythromycin is known to potently inhibit the cytochrome P450 isoform CYP3A4, which can affect the metabolism of numerous clinically relevant medications.{22760,20981} Erythromycin lactobionate is a soluble salt of erythromycin that is typically used for intraperitoneal or intravenous injections.{28247,28248}
Brand:CaymanSKU:-Out of stock
Erythromycin (Item No. 16486) is a macrolide antibiotic that inhibits bacterial protein synthesis by targeting the 50S ribosomal subunit, blocking the progression of nascent polypeptide chains.{22680} It is effective against a host of bacterial genera, including Streptococcus, Staphylococcus, and Haemophilus (MIC90s range from 0.015-2.0 mg/l).{22758} Erythromycin is known to potently inhibit the cytochrome P450 isoform CYP3A4, which can affect the metabolism of numerous clinically relevant medications.{22760,20981} Erythromycin lactobionate is a soluble salt of erythromycin that is typically used for intraperitoneal or intravenous injections.{28247,28248}
Brand:CaymanSKU:-Out of stock
Erythromycylamine is a macrolide antibiotic and an active metabolite of dirithromycin (Item No. 19466).{31455} It is active against a variety of bacteria, including strains of S. pyogenes, S. pneumoniae, L. monocytogenes, and B. pertussis (MICs = 0.06-0.12, 0.06-0.12, 1-2, and 0.015-0.25 µg/ml, respectively). It is also active against 28 clinical isolates of M. avium complex (MAC) isolated from patients with AIDS (MICs = 4-16 µg/ml).{47498} Erythromycylamine inhibits polylysine and polyproline synthesis in a cell-free assay.{47499}
Brand:CaymanSKU:28098 - 1 mgAvailable on backorder
Erythromycylamine is a macrolide antibiotic and an active metabolite of dirithromycin (Item No. 19466).{31455} It is active against a variety of bacteria, including strains of S. pyogenes, S. pneumoniae, L. monocytogenes, and B. pertussis (MICs = 0.06-0.12, 0.06-0.12, 1-2, and 0.015-0.25 µg/ml, respectively). It is also active against 28 clinical isolates of M. avium complex (MAC) isolated from patients with AIDS (MICs = 4-16 µg/ml).{47498} Erythromycylamine inhibits polylysine and polyproline synthesis in a cell-free assay.{47499}
Brand:CaymanSKU:28098 - 10 mgAvailable on backorder
Erythromycylamine is a macrolide antibiotic and an active metabolite of dirithromycin (Item No. 19466).{31455} It is active against a variety of bacteria, including strains of S. pyogenes, S. pneumoniae, L. monocytogenes, and B. pertussis (MICs = 0.06-0.12, 0.06-0.12, 1-2, and 0.015-0.25 µg/ml, respectively). It is also active against 28 clinical isolates of M. avium complex (MAC) isolated from patients with AIDS (MICs = 4-16 µg/ml).{47498} Erythromycylamine inhibits polylysine and polyproline synthesis in a cell-free assay.{47499}
Brand:CaymanSKU:28098 - 5 mgAvailable on backorder
Erythrosin B is a red fluorescein dye and an inhibitor of dopamine reuptake (IC50 = 45 µM in rat brain synaptosomes).{60093,60094,60095} It has been used in the colorimetric and fluorescent determination of protein concentrations in vitro.{60093,60094} Formulations containing erythrosine B have been used as color additives in food and pharmaceutical preparations.
Brand:CaymanSKU:31722 - 100 gAvailable on backorder
Erythrosin B is a red fluorescein dye and an inhibitor of dopamine reuptake (IC50 = 45 µM in rat brain synaptosomes).{60093,60094,60095} It has been used in the colorimetric and fluorescent determination of protein concentrations in vitro.{60093,60094} Formulations containing erythrosine B have been used as color additives in food and pharmaceutical preparations.
Brand:CaymanSKU:31722 - 25 gAvailable on backorder
Erythrosin B is a red fluorescein dye and an inhibitor of dopamine reuptake (IC50 = 45 µM in rat brain synaptosomes).{60093,60094,60095} It has been used in the colorimetric and fluorescent determination of protein concentrations in vitro.{60093,60094} Formulations containing erythrosine B have been used as color additives in food and pharmaceutical preparations.
Brand:CaymanSKU:31722 - 250 gAvailable on backorder
Erythrosin B is a red fluorescein dye and an inhibitor of dopamine reuptake (IC50 = 45 µM in rat brain synaptosomes).{60093,60094,60095} It has been used in the colorimetric and fluorescent determination of protein concentrations in vitro.{60093,60094} Formulations containing erythrosine B have been used as color additives in food and pharmaceutical preparations.
Brand:CaymanSKU:31722 - 50 gAvailable on backorder
Escitalopram ((S)-citalopram) is a selective serotonin reuptake inhibitor.{38120} It blocks serotonin reuptake in rat brain synaptosomes (IC50 = 2.1 nM) without affecting norepinephrine or dopamine reuptake.{38121} Escitalopram is more potent than the racemic mixture citalopram (Item No. 14572) or (R)-citalopram (IC50s = 3.9 and 280 nM, respectively).{38122} Formulations containing escitalopram have been used to treat anxiety in depressive disorders, post-traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD) and panic disorders.{38120}
Brand:CaymanSKU:22405 -Out of stock
Escitalopram ((S)-citalopram) is a selective serotonin reuptake inhibitor.{38120} It blocks serotonin reuptake in rat brain synaptosomes (IC50 = 2.1 nM) without affecting norepinephrine or dopamine reuptake.{38121} Escitalopram is more potent than the racemic mixture citalopram (Item No. 14572) or (R)-citalopram (IC50s = 3.9 and 280 nM, respectively).{38122} Formulations containing escitalopram have been used to treat anxiety in depressive disorders, post-traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD) and panic disorders.{38120}
Brand:CaymanSKU:22405 -Out of stock
Escitalopram ((S)-citalopram) is a selective serotonin reuptake inhibitor.{38120} It blocks serotonin reuptake in rat brain synaptosomes (IC50 = 2.1 nM) without affecting norepinephrine or dopamine reuptake.{38121} Escitalopram is more potent than the racemic mixture citalopram (Item No. 14572) or (R)-citalopram (IC50s = 3.9 and 280 nM, respectively).{38122} Formulations containing escitalopram have been used to treat anxiety in depressive disorders, post-traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD) and panic disorders.{38120}
Brand:CaymanSKU:22405 -Out of stock
Escitalopram ((S)-citalopram) is a selective serotonin reuptake inhibitor.{38120} It blocks serotonin reuptake in rat brain synaptosomes (IC50 = 2.1 nM) without affecting norepinephrine or dopamine reuptake.{38121} Escitalopram is more potent than the racemic mixture citalopram (Item No. 14572) or (R)-citalopram (IC50s = 3.9 and 280 nM, respectively).{38122} Formulations containing escitalopram have been used to treat anxiety in depressive disorders, post-traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD) and panic disorders.{38120}
Brand:CaymanSKU:22405 -Out of stock
Esculetin is a coumarin that has been found in Euphorbia and has diverse biological activities.{652,27801,57262,31766,57263} It inhibits 5-lipoxygenase (5-LO) and 12-LO (IC50s = 4 and 2.5 µM, respectively), as well as the histone demethylase jumonji AT-rich interactive domain 1B (JARID1B; IC50 = 4.6 µM).{652,27801} Esculetin is active against B. cereus, S. lutea, S. aureus, S. lactis, A. faecalis, and E. coli.{57262} It reduces production of hydrogen peroxide induced by the leucin-rich repeat kinase 2 (LRRK2) mutant LRRK2G2019S, which is linked to neurotoxicity and Parkinson’s disease, in Drosophila brain lysates and decreases cell death in LRRK2G2019S-expressing primary human cortical neurons.{31766} Esculetin (1.68 µmol/ear) reduces croton oil-induced ear edema in mice.{57263} It also inhibits acetylcholine-induced writhing in mice (ED50 = 69 mg/kg).
Brand:CaymanSKU:-Available on backorder
Esculetin is a coumarin that has been found in Euphorbia and has diverse biological activities.{652,27801,57262,31766,57263} It inhibits 5-lipoxygenase (5-LO) and 12-LO (IC50s = 4 and 2.5 µM, respectively), as well as the histone demethylase jumonji AT-rich interactive domain 1B (JARID1B; IC50 = 4.6 µM).{652,27801} Esculetin is active against B. cereus, S. lutea, S. aureus, S. lactis, A. faecalis, and E. coli.{57262} It reduces production of hydrogen peroxide induced by the leucin-rich repeat kinase 2 (LRRK2) mutant LRRK2G2019S, which is linked to neurotoxicity and Parkinson’s disease, in Drosophila brain lysates and decreases cell death in LRRK2G2019S-expressing primary human cortical neurons.{31766} Esculetin (1.68 µmol/ear) reduces croton oil-induced ear edema in mice.{57263} It also inhibits acetylcholine-induced writhing in mice (ED50 = 69 mg/kg).
Brand:CaymanSKU:-Available on backorder
Esculetin is a coumarin that has been found in Euphorbia and has diverse biological activities.{652,27801,57262,31766,57263} It inhibits 5-lipoxygenase (5-LO) and 12-LO (IC50s = 4 and 2.5 µM, respectively), as well as the histone demethylase jumonji AT-rich interactive domain 1B (JARID1B; IC50 = 4.6 µM).{652,27801} Esculetin is active against B. cereus, S. lutea, S. aureus, S. lactis, A. faecalis, and E. coli.{57262} It reduces production of hydrogen peroxide induced by the leucin-rich repeat kinase 2 (LRRK2) mutant LRRK2G2019S, which is linked to neurotoxicity and Parkinson’s disease, in Drosophila brain lysates and decreases cell death in LRRK2G2019S-expressing primary human cortical neurons.{31766} Esculetin (1.68 µmol/ear) reduces croton oil-induced ear edema in mice.{57263} It also inhibits acetylcholine-induced writhing in mice (ED50 = 69 mg/kg).
Brand:CaymanSKU:-Available on backorder
Esculetin is a coumarin that has been found in Euphorbia and has diverse biological activities.{652,27801,57262,31766,57263} It inhibits 5-lipoxygenase (5-LO) and 12-LO (IC50s = 4 and 2.5 µM, respectively), as well as the histone demethylase jumonji AT-rich interactive domain 1B (JARID1B; IC50 = 4.6 µM).{652,27801} Esculetin is active against B. cereus, S. lutea, S. aureus, S. lactis, A. faecalis, and E. coli.{57262} It reduces production of hydrogen peroxide induced by the leucin-rich repeat kinase 2 (LRRK2) mutant LRRK2G2019S, which is linked to neurotoxicity and Parkinson’s disease, in Drosophila brain lysates and decreases cell death in LRRK2G2019S-expressing primary human cortical neurons.{31766} Esculetin (1.68 µmol/ear) reduces croton oil-induced ear edema in mice.{57263} It also inhibits acetylcholine-induced writhing in mice (ED50 = 69 mg/kg).
Brand:CaymanSKU:-Available on backorder
ESI-05 is an inhibitor of exchange protein activated by cAMP 2 (Epac2) that inhibits cAMP-induced Epac2 guanine nucleotide exchange factor (GEF) activity with an IC50 value of 0.43 µM in a cell-free assay.{46657} It is selective for Epac2 over Epac1 and PKA at 25 µM. ESI-05 (1, 5, 10, and 25 µM) reduces activation of the GTPase RAP1 induced by the Epac-selective cAMP analog 007-AM in HEK293 cells expressing Epac2 but has no effect in HEK293 cells expressing Epac1.
Brand:CaymanSKU:29702 - 1 mgAvailable on backorder
ESI-05 is an inhibitor of exchange protein activated by cAMP 2 (Epac2) that inhibits cAMP-induced Epac2 guanine nucleotide exchange factor (GEF) activity with an IC50 value of 0.43 µM in a cell-free assay.{46657} It is selective for Epac2 over Epac1 and PKA at 25 µM. ESI-05 (1, 5, 10, and 25 µM) reduces activation of the GTPase RAP1 induced by the Epac-selective cAMP analog 007-AM in HEK293 cells expressing Epac2 but has no effect in HEK293 cells expressing Epac1.
Brand:CaymanSKU:29702 - 10 mgAvailable on backorder
ESI-05 is an inhibitor of exchange protein activated by cAMP 2 (Epac2) that inhibits cAMP-induced Epac2 guanine nucleotide exchange factor (GEF) activity with an IC50 value of 0.43 µM in a cell-free assay.{46657} It is selective for Epac2 over Epac1 and PKA at 25 µM. ESI-05 (1, 5, 10, and 25 µM) reduces activation of the GTPase RAP1 induced by the Epac-selective cAMP analog 007-AM in HEK293 cells expressing Epac2 but has no effect in HEK293 cells expressing Epac1.
Brand:CaymanSKU:29702 - 25 mgAvailable on backorder
ESI-05 is an inhibitor of exchange protein activated by cAMP 2 (Epac2) that inhibits cAMP-induced Epac2 guanine nucleotide exchange factor (GEF) activity with an IC50 value of 0.43 µM in a cell-free assay.{46657} It is selective for Epac2 over Epac1 and PKA at 25 µM. ESI-05 (1, 5, 10, and 25 µM) reduces activation of the GTPase RAP1 induced by the Epac-selective cAMP analog 007-AM in HEK293 cells expressing Epac2 but has no effect in HEK293 cells expressing Epac1.
Brand:CaymanSKU:29702 - 5 mgAvailable on backorder
Exchange protein activated by cAMP (Epac) proteins mediate cAMP signaling independent of protein kinase A (PKA). ESI-09 is an inhibitor of Epac1 and Epac2 with IC50 values of 3.2 and 1.4 µM, respectively. It shows no activity against PKA at concentrations as high as 25 µM.{30918,30919} ESI-09 has been shown to block Akt phosphorylation and insulin secretion in pancreatic β cells, as well as to block the migration of AsPC-1 and PANC-1 pancreatic cancer cells in vitro.{30918,30919}
Brand:CaymanSKU:-Available on backorder
Exchange protein activated by cAMP (Epac) proteins mediate cAMP signaling independent of protein kinase A (PKA). ESI-09 is an inhibitor of Epac1 and Epac2 with IC50 values of 3.2 and 1.4 µM, respectively. It shows no activity against PKA at concentrations as high as 25 µM.{30918,30919} ESI-09 has been shown to block Akt phosphorylation and insulin secretion in pancreatic β cells, as well as to block the migration of AsPC-1 and PANC-1 pancreatic cancer cells in vitro.{30918,30919}
Brand:CaymanSKU:-Available on backorder
Exchange protein activated by cAMP (Epac) proteins mediate cAMP signaling independent of protein kinase A (PKA). ESI-09 is an inhibitor of Epac1 and Epac2 with IC50 values of 3.2 and 1.4 µM, respectively. It shows no activity against PKA at concentrations as high as 25 µM.{30918,30919} ESI-09 has been shown to block Akt phosphorylation and insulin secretion in pancreatic β cells, as well as to block the migration of AsPC-1 and PANC-1 pancreatic cancer cells in vitro.{30918,30919}
Brand:CaymanSKU:-Available on backorder
Exchange protein activated by cAMP (Epac) proteins mediate cAMP signaling independent of protein kinase A (PKA). ESI-09 is an inhibitor of Epac1 and Epac2 with IC50 values of 3.2 and 1.4 µM, respectively. It shows no activity against PKA at concentrations as high as 25 µM.{30918,30919} ESI-09 has been shown to block Akt phosphorylation and insulin secretion in pancreatic β cells, as well as to block the migration of AsPC-1 and PANC-1 pancreatic cancer cells in vitro.{30918,30919}
Brand:CaymanSKU:-Available on backorder
Eslicarbazepine acetate is a sodium channel blocker (IC50 = 138 nM in a radioligand binding assay).{40363} It inhibits sodium uptake in a dose-dependent manner in rat cortical synaptosomes at concentrations ranging from 30-300 μM. In vivo, oral and i.p. administration of eslicarbazepine acetate is protective against seizures induced by maximal electroshock (MES) in mice with ED50 values of 4.7 and 6.3 mg/kg, respectively, which are well below the median toxic dose (TD50) values of 358.7 and 78.6 mg/kg for oral and i.p. administration respectively. High-dose administration (30 mg/kg) of eslicarbazepine acetate prevents picrotoxin-induced seizures in rats.{40364} Low-dose administration (10 mg/kg) does not suppress picrotoxin-induced seizures, however, it reduces seizure number and duration. Formulations containing eslicarbazepine acetate have been used for the treatment of partial-onset seizures.{40365}
Brand:CaymanSKU:23656 - 10 mgAvailable on backorder
Eslicarbazepine acetate is a sodium channel blocker (IC50 = 138 nM in a radioligand binding assay).{40363} It inhibits sodium uptake in a dose-dependent manner in rat cortical synaptosomes at concentrations ranging from 30-300 μM. In vivo, oral and i.p. administration of eslicarbazepine acetate is protective against seizures induced by maximal electroshock (MES) in mice with ED50 values of 4.7 and 6.3 mg/kg, respectively, which are well below the median toxic dose (TD50) values of 358.7 and 78.6 mg/kg for oral and i.p. administration respectively. High-dose administration (30 mg/kg) of eslicarbazepine acetate prevents picrotoxin-induced seizures in rats.{40364} Low-dose administration (10 mg/kg) does not suppress picrotoxin-induced seizures, however, it reduces seizure number and duration. Formulations containing eslicarbazepine acetate have been used for the treatment of partial-onset seizures.{40365}
Brand:CaymanSKU:23656 - 25 mgAvailable on backorder
Eslicarbazepine acetate is a sodium channel blocker (IC50 = 138 nM in a radioligand binding assay).{40363} It inhibits sodium uptake in a dose-dependent manner in rat cortical synaptosomes at concentrations ranging from 30-300 μM. In vivo, oral and i.p. administration of eslicarbazepine acetate is protective against seizures induced by maximal electroshock (MES) in mice with ED50 values of 4.7 and 6.3 mg/kg, respectively, which are well below the median toxic dose (TD50) values of 358.7 and 78.6 mg/kg for oral and i.p. administration respectively. High-dose administration (30 mg/kg) of eslicarbazepine acetate prevents picrotoxin-induced seizures in rats.{40364} Low-dose administration (10 mg/kg) does not suppress picrotoxin-induced seizures, however, it reduces seizure number and duration. Formulations containing eslicarbazepine acetate have been used for the treatment of partial-onset seizures.{40365}
Brand:CaymanSKU:23656 - 5 mgAvailable on backorder
Eslicarbazepine acetate is a sodium channel blocker (IC50 = 138 nM in a radioligand binding assay).{40363} It inhibits sodium uptake in a dose-dependent manner in rat cortical synaptosomes at concentrations ranging from 30-300 μM. In vivo, oral and i.p. administration of eslicarbazepine acetate is protective against seizures induced by maximal electroshock (MES) in mice with ED50 values of 4.7 and 6.3 mg/kg, respectively, which are well below the median toxic dose (TD50) values of 358.7 and 78.6 mg/kg for oral and i.p. administration respectively. High-dose administration (30 mg/kg) of eslicarbazepine acetate prevents picrotoxin-induced seizures in rats.{40364} Low-dose administration (10 mg/kg) does not suppress picrotoxin-induced seizures, however, it reduces seizure number and duration. Formulations containing eslicarbazepine acetate have been used for the treatment of partial-onset seizures.{40365}
Brand:CaymanSKU:23656 - 50 mgAvailable on backorder
Esmolol is a β1-adrenergic receptor (β1-AR) antagonist.{36081} It binds to β1-ARs (Kd = 100 nM in isolated cardiac myocytes) and is 34-fold selective for β1- over β2-ARs.{36081,54302} Esmolol also inhibits L-type Ca2+ currents (ICa.L) and the fast Na+ current (INa) in rat cardiac myocytes (IC50s = 50 and 169 μM, respectively), which results in complete ventricular arrest at concentrations greater than or equal to 1 mM.{36081} Formulations containing esmolol have been used in the treatment of cardiac arrhythmias, postoperative hypertension, and acute ischemic heart disease, as well as to minimize myocardial contraction during cardiac surgery and attenuate the adrenergic response associated with tracheal intubation.
Brand:CaymanSKU:22581 -Out of stock
Esmolol is a β1-adrenergic receptor (β1-AR) antagonist.{36081} It binds to β1-ARs (Kd = 100 nM in isolated cardiac myocytes) and is 34-fold selective for β1- over β2-ARs.{36081,54302} Esmolol also inhibits L-type Ca2+ currents (ICa.L) and the fast Na+ current (INa) in rat cardiac myocytes (IC50s = 50 and 169 μM, respectively), which results in complete ventricular arrest at concentrations greater than or equal to 1 mM.{36081} Formulations containing esmolol have been used in the treatment of cardiac arrhythmias, postoperative hypertension, and acute ischemic heart disease, as well as to minimize myocardial contraction during cardiac surgery and attenuate the adrenergic response associated with tracheal intubation.
Brand:CaymanSKU:22581 -Out of stock
Esmolol is a β1-adrenergic receptor (β1-AR) antagonist.{36081} It binds to β1-ARs (Kd = 100 nM in isolated cardiac myocytes) and is 34-fold selective for β1- over β2-ARs.{36081,54302} Esmolol also inhibits L-type Ca2+ currents (ICa.L) and the fast Na+ current (INa) in rat cardiac myocytes (IC50s = 50 and 169 μM, respectively), which results in complete ventricular arrest at concentrations greater than or equal to 1 mM.{36081} Formulations containing esmolol have been used in the treatment of cardiac arrhythmias, postoperative hypertension, and acute ischemic heart disease, as well as to minimize myocardial contraction during cardiac surgery and attenuate the adrenergic response associated with tracheal intubation.
Brand:CaymanSKU:22581 -Out of stock
Esmolol is a β1-adrenergic receptor (β1-AR) antagonist.{36081} It binds to β1-ARs (Kd = 100 nM in isolated cardiac myocytes) and is 34-fold selective for β1- over β2-ARs.{36081,54302} Esmolol also inhibits L-type Ca2+ currents (ICa.L) and the fast Na+ current (INa) in rat cardiac myocytes (IC50s = 50 and 169 μM, respectively), which results in complete ventricular arrest at concentrations greater than or equal to 1 mM.{36081} Formulations containing esmolol have been used in the treatment of cardiac arrhythmias, postoperative hypertension, and acute ischemic heart disease, as well as to minimize myocardial contraction during cardiac surgery and attenuate the adrenergic response associated with tracheal intubation.
Brand:CaymanSKU:22581 -Out of stock
Esmolol-d7 is intended for use as an internal standard for the quantification of esmolol (Item No. 22581) by GC- or LC-MS. Esmolol is a β1-adrenergic receptor (β1-AR) antagonist.{36081} It binds to β1-ARs (Kd = 100 nM in isolated cardiac myocytes) and is 34-fold selective for β1- over β2-ARs.{36081,54302} Esmolol also inhibits L-type Ca2+ currents (ICa.L) and the fast Na+ current (INa) in rat cardiac myocytes (IC50s = 50 and 169 μM, respectively), which results in complete ventricular arrest at concentrations greater than or equal to 1 mM.{36081} Formulations containing esmolol have been used in the treatment of cardiac arrhythmias, postoperative hypertension, and acute ischemic heart disease, as well as to minimize myocardial contraction during cardiac surgery and attenuate the adrenergic response associated with tracheal intubation.
Brand:CaymanSKU:30727 - 1 mgAvailable on backorder
Esmolol-d7 is intended for use as an internal standard for the quantification of esmolol (Item No. 22581) by GC- or LC-MS. Esmolol is a β1-adrenergic receptor (β1-AR) antagonist.{36081} It binds to β1-ARs (Kd = 100 nM in isolated cardiac myocytes) and is 34-fold selective for β1- over β2-ARs.{36081,54302} Esmolol also inhibits L-type Ca2+ currents (ICa.L) and the fast Na+ current (INa) in rat cardiac myocytes (IC50s = 50 and 169 μM, respectively), which results in complete ventricular arrest at concentrations greater than or equal to 1 mM.{36081} Formulations containing esmolol have been used in the treatment of cardiac arrhythmias, postoperative hypertension, and acute ischemic heart disease, as well as to minimize myocardial contraction during cardiac surgery and attenuate the adrenergic response associated with tracheal intubation.
Brand:CaymanSKU:30727 - 10 mgAvailable on backorder
Esmolol-d7 is intended for use as an internal standard for the quantification of esmolol (Item No. 22581) by GC- or LC-MS. Esmolol is a β1-adrenergic receptor (β1-AR) antagonist.{36081} It binds to β1-ARs (Kd = 100 nM in isolated cardiac myocytes) and is 34-fold selective for β1- over β2-ARs.{36081,54302} Esmolol also inhibits L-type Ca2+ currents (ICa.L) and the fast Na+ current (INa) in rat cardiac myocytes (IC50s = 50 and 169 μM, respectively), which results in complete ventricular arrest at concentrations greater than or equal to 1 mM.{36081} Formulations containing esmolol have been used in the treatment of cardiac arrhythmias, postoperative hypertension, and acute ischemic heart disease, as well as to minimize myocardial contraction during cardiac surgery and attenuate the adrenergic response associated with tracheal intubation.
Brand:CaymanSKU:30727 - 5 mgAvailable on backorder
Esmolol-d7 is intended for use as an internal standard for the quantification of esmolol (Item No. 22581) by GC- or LC-MS. Esmolol is a β1-adrenergic receptor (β1-AR) antagonist.{36081} It binds to β1-ARs (Kd = 100 nM in isolated cardiac myocytes) and is 34-fold selective for β1- over β2-ARs.{36081,54302} Esmolol also inhibits L-type Ca2+ currents (ICa.L) and the fast Na+ current (INa) in rat cardiac myocytes (IC50s = 50 and 169 μM, respectively), which results in complete ventricular arrest at concentrations greater than or equal to 1 mM.{36081} Formulations containing esmolol have been used in the treatment of cardiac arrhythmias, postoperative hypertension, and acute ischemic heart disease, as well as to minimize myocardial contraction during cardiac surgery and attenuate the adrenergic response associated with tracheal intubation.
Brand:CaymanSKU:30727 - 500 µgAvailable on backorder
Esomeprazole, the (S)-enantiomer of omeprazole (Item No. 14880), is a selective inhibitor of the gastric H+/K+ ATPase.{18249} It is highly effective at inhibiting gastric acid secretion and demonstrates lower first-pass hepatic metabolism and slower plasma clearance, resulting in increased bioavailability compared to omeprazole.{18249,28643} Esomeprazole is predominantly metabolized by the cytochrome P450 (CYP) isomer CYP3A4.{18249}
Brand:CaymanSKU:-Available on backorder
Esomeprazole, the (S)-enantiomer of omeprazole (Item No. 14880), is a selective inhibitor of the gastric H+/K+ ATPase.{18249} It is highly effective at inhibiting gastric acid secretion and demonstrates lower first-pass hepatic metabolism and slower plasma clearance, resulting in increased bioavailability compared to omeprazole.{18249,28643} Esomeprazole is predominantly metabolized by the cytochrome P450 (CYP) isomer CYP3A4.{18249}
Brand:CaymanSKU:-Available on backorder
Esomeprazole, the (S)-enantiomer of omeprazole (Item No. 14880), is a selective inhibitor of the gastric H+/K+ ATPase.{18249} It is highly effective at inhibiting gastric acid secretion and demonstrates lower first-pass hepatic metabolism and slower plasma clearance, resulting in increased bioavailability compared to omeprazole.{18249,28643} Esomeprazole is predominantly metabolized by the cytochrome P450 (CYP) isomer CYP3A4.{18249}
Brand:CaymanSKU:-Available on backorder
Estradiol 17-(β-D-glucuronide) (E217G) is an estrogen metabolite formed in the liver and subsequently excreted in bile.{26342} It acts as a substrate of the multidrug resistance protein 2 (MRP2; Km = 75 µM), and through MRP2-mediated transport, functions as a cholestatic agent, decreasing bile flow.{26342,26341} In addition to binding to the MRP2 transport site, E217G has been shown to bind to an allosteric site that through positive cooperativity activates its own transport via MRP2 and the transport of other MRP2 substrates, including the non-cholestatic estrogen metabolite, estradiol 3-(β-D-glucuronide) (E23G; Item No. 16155).{26341,26340} E217G has also been reported to be transported by MDR1, MRP1, MRP3, MRP4, MRP7, ABCG2 (a breast cancer resistance protein transporter), and the rat organic anion-transporting polypeptides 1-4.{26341}
Brand:CaymanSKU:-